Abstract
86 of 98 patients completed the 12-month follow-up. Totally, headache frequency was reduced by 39% (p<0.001), medication use by 63% (p<0.001) and 83% remained cured of MOH. Headache frequency was reduced with more than 50% in 42 patients (49%) and 52 (61%) reverted to episodic headache, and with no difference between the groups. Patients in programme B used significantly less symptomatic medication: 6.5 days/ 4 weeks compared with 8.7 days/4 weeks in programme A (p=0.02), and the 56% of patients in programme B who needed prophylactic medication was significantly less than the 80% in programme A (p=0.02). Further, programme B required fewer resources from the staff. Conclusion Structured detoxification with close follow-up by a multidisciplinary team for one year is highly effective in patients with previously treatment-resistant MOH. We recommend a multidisciplinary educational programme for patients in groups due to cost-effectiveness and limited use of medication.
Highlights
The strategy regarding whether detoxification for medication overuse headache (MOH) is needed or not has been heavily debated
Patients in programme B used significantly less symptomatic medication: 6.5 days/ 4 weeks compared with 8.7 days/4 weeks in programme A (p=0.02), and the 56% of patients in programme B who needed prophylactic medication was significantly less than the 80% in programme A (p=0.02)
MOH patients who had previously been unsuccessfully treated by neurologists were enrolled in one of 2 structured detoxification programmes in a tertiary headache centre: A) a one-week withdrawal with restricted analgesics, rescue medications and prophylactics from Day 1 followed by advice of restricted intake of symptomatic medications or B) a 2-month drug-free period and multidisciplinary education in groups and subsequent initiation of restricted symptomatic medication and prophylactics as required
Summary
The strategy regarding whether detoxification for medication overuse headache (MOH) is needed or not has been heavily debated. Patients are often regarded as treatment resistant if they fail one withdrawal attempt. Many report a substantial relapse to MOH within the first year after withdrawal. Patients in programme B used significantly less symptomatic medication: 6.5 days/ 4 weeks compared with 8.7 days/4 weeks in programme A (p=0.02), and the 56% of patients in programme B who needed prophylactic medication was significantly less than the 80% in programme A (p=0.02). Programme B required fewer resources from the staff
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
